Details:
The collaboration will leverage Phenomic’s expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer’s efforts to develop first-in-class medicines important in stroma-rich cancers.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $509.0 million Upfront Cash: $9.0 million
Deal Type: Collaboration November 29, 2023
Details:
Under the collaboration, AbCellera and Incyte will discover and develop therapeutic antibodies in oncology and Incyte will have the right to develop and commercialize therapeutic antibodies resulting from the collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 13, 2023
Details:
The collaboration will combine ImmunoGen's proprietary linker-payload technology with ImmunoBiochem's antibodies directed against specific targets to develop next-generation antibody-drug conjugates.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Immunogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 24, 2023
Details:
The multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s AI-enabled screening platform to discover small molecule modulators of up to five oncology targets across an initial 18-month term.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Tavros Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 27, 2023
Details:
The research collaboration will focus on the discovery and development of novel targets to enhance tumor cell responsiveness to chemotherapy and immunotherapies in specific cancers including lung, head and neck, cervical, and bladder cancers.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Harvard Medical School
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 29, 2022
Details:
Under the terms of the commercial agreement, Bayer will purchase high-purity Ac-225 from BWXT Medical at pre-determined prices. Ac-225 is a highly powerful radioisotope used in targeted alpha therapies (TATs).
Lead Product(s): Acc-225
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 27, 2022
Details:
The collaboration leverages Fusion’s Targeted Alpha Therapies (TATs) platform and expertise in radiopharmaceuticals with AstraZeneca’s leading portfolio of antibodies and cancer therapeutics, including DNA Damage Response Inhibitors (DDRis).
Lead Product(s): Radioactive labelled-antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 02, 2020